NO311069B1 - Pyridylbisfosfonater for anvendelse som terapeutisk middel - Google Patents
Pyridylbisfosfonater for anvendelse som terapeutisk middel Download PDFInfo
- Publication number
- NO311069B1 NO311069B1 NO19965228A NO965228A NO311069B1 NO 311069 B1 NO311069 B1 NO 311069B1 NO 19965228 A NO19965228 A NO 19965228A NO 965228 A NO965228 A NO 965228A NO 311069 B1 NO311069 B1 NO 311069B1
- Authority
- NO
- Norway
- Prior art keywords
- methylidene
- pyridinyl
- amino
- bisphosphonic acid
- tetraethyl ester
- Prior art date
Links
- -1 Pyridyl bisphosphonates Chemical class 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims description 4
- 229940124597 therapeutic agent Drugs 0.000 title claims description 4
- 229940122361 Bisphosphonate Drugs 0.000 title description 12
- 239000002253 acid Substances 0.000 claims abstract description 15
- 208000020084 Bone disease Diseases 0.000 claims abstract description 13
- 150000002148 esters Chemical class 0.000 claims abstract description 12
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 6
- 208000010191 Osteitis Deformans Diseases 0.000 claims abstract description 6
- 208000027868 Paget disease Diseases 0.000 claims abstract description 6
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- 230000036210 malignancy Effects 0.000 claims abstract description 6
- 208000027202 mammary Paget disease Diseases 0.000 claims abstract description 6
- 230000000010 osteolytic effect Effects 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- QIQUTPLWYZYIAV-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-2-chloropyridin-3-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=CC=CN=C1Cl QIQUTPLWYZYIAV-UHFFFAOYSA-N 0.000 claims description 4
- ATDDKJIMVUNDTI-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]pyridin-2-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=CC=CC=N1 ATDDKJIMVUNDTI-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
- HQWJNWAHFHTGIO-UHFFFAOYSA-N 2-[bis(diethoxyphosphoryl)methylamino]pyridin-3-ol Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=NC=CC=C1O HQWJNWAHFHTGIO-UHFFFAOYSA-N 0.000 claims description 3
- SNPOFESFECHNNO-UHFFFAOYSA-N 6-n-[bis(diethoxyphosphoryl)methyl]pyridine-2,6-diamine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=CC=CC(N)=N1 SNPOFESFECHNNO-UHFFFAOYSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
- YHWKWEYVRJJRRU-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-3,5-dichloropyridin-2-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=NC=C(Cl)C=C1Cl YHWKWEYVRJJRRU-UHFFFAOYSA-N 0.000 claims description 3
- GLKMFGKDNJKVAZ-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-3-nitropyridin-2-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=NC=CC=C1[N+]([O-])=O GLKMFGKDNJKVAZ-UHFFFAOYSA-N 0.000 claims description 3
- CDHPKZPLJHNZRH-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-3-phenylmethoxypyridin-2-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=NC=CC=C1OCC1=CC=CC=C1 CDHPKZPLJHNZRH-UHFFFAOYSA-N 0.000 claims description 3
- IXZKBDFCYDBFPG-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-5-chloropyridin-2-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=CC=C(Cl)C=N1 IXZKBDFCYDBFPG-UHFFFAOYSA-N 0.000 claims description 3
- QEOYHQSTBLSRIX-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-5-methoxypyridin-2-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=CC=C(OC)C=N1 QEOYHQSTBLSRIX-UHFFFAOYSA-N 0.000 claims description 3
- TZINUFUSDFOAEZ-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-5-phenylmethoxypyridin-2-amine Chemical compound C1=NC(NC(P(=O)(OCC)OCC)P(=O)(OCC)OCC)=CC=C1OCC1=CC=CC=C1 TZINUFUSDFOAEZ-UHFFFAOYSA-N 0.000 claims description 3
- WOTVYFKWUUUDDX-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-6-chloropyridin-3-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=CC=C(Cl)N=C1 WOTVYFKWUUUDDX-UHFFFAOYSA-N 0.000 claims description 3
- QJUOKDGLMFUPJD-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-6-methoxypyridin-3-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=CC=C(OC)N=C1 QJUOKDGLMFUPJD-UHFFFAOYSA-N 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- PFWHSBDSVRROKL-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-5-nitropyridin-2-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=CC=C([N+]([O-])=O)C=N1 PFWHSBDSVRROKL-UHFFFAOYSA-N 0.000 claims description 2
- PMXXJZXMAYEESJ-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]pyridin-4-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=CC=NC=C1 PMXXJZXMAYEESJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- NDYDFSOELCPQRV-UHFFFAOYSA-N (amino-phosphono-pyridin-2-ylmethyl)phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(N)C1=CC=CC=N1 NDYDFSOELCPQRV-UHFFFAOYSA-N 0.000 claims 1
- 125000004702 alkoxy alkyl carbonyl group Chemical group 0.000 claims 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 9
- 208000006386 Bone Resorption Diseases 0.000 description 8
- 239000004098 Tetracycline Substances 0.000 description 8
- 150000004663 bisphosphonates Chemical class 0.000 description 8
- 230000024279 bone resorption Effects 0.000 description 8
- 229960002180 tetracycline Drugs 0.000 description 8
- 229930101283 tetracycline Natural products 0.000 description 8
- 235000019364 tetracycline Nutrition 0.000 description 8
- 150000003522 tetracyclines Chemical class 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- PNFHTBDRPOJJTQ-UHFFFAOYSA-N 1-[ethoxy(iodomethyl)phosphoryl]oxyethane Chemical compound CCOP(=O)(CI)OCC PNFHTBDRPOJJTQ-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- GBKUABJFKQMGAR-UHFFFAOYSA-N 5-[bis(diethoxyphosphoryl)methylamino]-1h-pyridin-2-one Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=CC=C(O)N=C1 GBKUABJFKQMGAR-UHFFFAOYSA-N 0.000 description 2
- ITCDTGHOLKSLEH-UHFFFAOYSA-N 6-[bis(diethoxyphosphoryl)methylamino]pyridin-3-ol Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=CC=C(O)C=N1 ITCDTGHOLKSLEH-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- FRCICXIVPRNPLM-UHFFFAOYSA-N [amino(phosphono)methyl]phosphonic acid Chemical class OP(=O)(O)C(N)P(O)(O)=O FRCICXIVPRNPLM-UHFFFAOYSA-N 0.000 description 2
- 235000021128 adult diet Nutrition 0.000 description 2
- 150000003927 aminopyridines Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 1
- BMTSZVZQNMNPCT-UHFFFAOYSA-N 2-aminopyridin-3-ol Chemical compound NC1=NC=CC=C1O BMTSZVZQNMNPCT-UHFFFAOYSA-N 0.000 description 1
- NMCBWICNRJLKKM-UHFFFAOYSA-N 3-(benzyloxy)pyridin-2-amine Chemical compound NC1=NC=CC=C1OCC1=CC=CC=C1 NMCBWICNRJLKKM-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MAXBVGJEFDMHNV-UHFFFAOYSA-N 5-chloropyridin-2-amine Chemical compound NC1=CC=C(Cl)C=N1 MAXBVGJEFDMHNV-UHFFFAOYSA-N 0.000 description 1
- MNRPDCYOPOOILG-UHFFFAOYSA-N 6-chloro-n-(diethoxyphosphorylmethyl)pyridin-3-amine Chemical compound CCOP(=O)(OCC)CNC1=CC=C(Cl)N=C1 MNRPDCYOPOOILG-UHFFFAOYSA-N 0.000 description 1
- QAJYCQZQLVENRZ-UHFFFAOYSA-N 6-chloropyridin-3-amine Chemical compound NC1=CC=C(Cl)N=C1 QAJYCQZQLVENRZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OQCPIONDYBPDIO-UHFFFAOYSA-N C(C)OP(OCC)(=O)C(P(OCC)(OCC)=O)NC1=NC=CC=C1O.C(C)OP(OCC)(=O)C(P(OCC)(OCC)=O)NC1=NC=CC=C1 Chemical compound C(C)OP(OCC)(=O)C(P(OCC)(OCC)=O)NC1=NC=CC=C1O.C(C)OP(OCC)(=O)C(P(OCC)(OCC)=O)NC1=NC=CC=C1 OQCPIONDYBPDIO-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- DIMNVJMCMNJELI-UHFFFAOYSA-N [[[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]-phosphonomethyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1=NC=C(C(F)(F)F)C=C1Cl DIMNVJMCMNJELI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000123 anti-resoprtive effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- CGTIWQMKDRPYCS-UHFFFAOYSA-N bromomethyl-[(6-chloropyridin-3-yl)amino]oxyphosphinic acid Chemical compound BrCP(=O)(O)ONC1=CC=C(Cl)N=C1 CGTIWQMKDRPYCS-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- UCQFCFPECQILOL-UHFFFAOYSA-N diethyl hydrogen phosphate Chemical compound CCOP(O)(=O)OCC UCQFCFPECQILOL-UHFFFAOYSA-N 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- VGGRCVDNFAQIKO-UHFFFAOYSA-N formic anhydride Chemical compound O=COC=O VGGRCVDNFAQIKO-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- STYLQUBKZVZETI-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-3,5-dimethoxypyridin-2-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=NC=C(OC)C=C1OC STYLQUBKZVZETI-UHFFFAOYSA-N 0.000 description 1
- XIJNUWMFOXTNHK-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-3-chloro-5-(trifluoromethyl)pyridin-2-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)NC1=NC=C(C(F)(F)F)C=C1Cl XIJNUWMFOXTNHK-UHFFFAOYSA-N 0.000 description 1
- SBKHYIYRFYZENU-UHFFFAOYSA-N n-[bis(diethoxyphosphoryl)methyl]-6-phenylmethoxypyridin-3-amine Chemical compound N1=CC(NC(P(=O)(OCC)OCC)P(=O)(OCC)OCC)=CC=C1OCC1=CC=CC=C1 SBKHYIYRFYZENU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OLAPPGSPBNVTRF-UHFFFAOYSA-N naphthalene-1,4,5,8-tetracarboxylic acid Chemical class C1=CC(C(O)=O)=C2C(C(=O)O)=CC=C(C(O)=O)C2=C1C(O)=O OLAPPGSPBNVTRF-UHFFFAOYSA-N 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical class O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- UKXAGBYRVKMKEA-UHFFFAOYSA-N phosphoric acid trihydrochloride Chemical compound Cl.Cl.Cl.P(O)(O)(O)=O UKXAGBYRVKMKEA-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9402001A SE9402001D0 (sv) | 1994-06-09 | 1994-06-09 | Pyridylbisphosphonates for use as a therapeutical agent |
| PCT/FI1995/000315 WO1995033466A1 (en) | 1994-06-09 | 1995-06-02 | Pyridylbisphosphonates for use as a therapeutical agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO965228D0 NO965228D0 (no) | 1996-12-06 |
| NO965228L NO965228L (no) | 1996-12-06 |
| NO311069B1 true NO311069B1 (no) | 2001-10-08 |
Family
ID=20394303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19965228A NO311069B1 (no) | 1994-06-09 | 1996-12-06 | Pyridylbisfosfonater for anvendelse som terapeutisk middel |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US5866556A (sv) |
| EP (1) | EP0762883B1 (sv) |
| JP (1) | JP3883137B2 (sv) |
| KR (1) | KR100363692B1 (sv) |
| CN (1) | CN1077792C (sv) |
| AT (1) | ATE208622T1 (sv) |
| AU (1) | AU691616B2 (sv) |
| BG (1) | BG63104B1 (sv) |
| BR (1) | BR9508185A (sv) |
| CZ (1) | CZ291477B6 (sv) |
| DE (1) | DE69523914T2 (sv) |
| DK (1) | DK0762883T3 (sv) |
| EE (1) | EE03475B1 (sv) |
| ES (1) | ES2162919T3 (sv) |
| HK (1) | HK1012572A1 (sv) |
| HU (1) | HU228618B1 (sv) |
| IS (1) | IS1801B (sv) |
| NO (1) | NO311069B1 (sv) |
| NZ (1) | NZ287094A (sv) |
| PL (1) | PL180705B1 (sv) |
| PT (1) | PT762883E (sv) |
| RO (1) | RO119433B1 (sv) |
| RU (1) | RU2154482C2 (sv) |
| SE (1) | SE9402001D0 (sv) |
| SK (1) | SK282650B6 (sv) |
| UA (1) | UA43918C2 (sv) |
| WO (1) | WO1995033466A1 (sv) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100763064B1 (ko) * | 1999-05-21 | 2007-10-04 | 노파르티스 아게 | 제약 조성물 및 용도 |
| WO2001044258A1 (en) * | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Novel heterocycles |
| US7115589B2 (en) | 1999-12-17 | 2006-10-03 | Ariad Pharmaceuticals, Inc. | Purine derivatives |
| EP1248790A1 (en) * | 1999-12-17 | 2002-10-16 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
| WO2002034269A1 (en) * | 2000-10-27 | 2002-05-02 | Schering Oy | Method for the preparation of a pharmaceutical composition, and its use |
| AU2003211022A1 (en) * | 2002-02-19 | 2003-09-09 | Ilex Products, Inc. | Aminodiphosphonate apolipoprotein e modulators |
| TW200413381A (en) * | 2002-11-04 | 2004-08-01 | Hoffmann La Roche | Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
| US20050010305A1 (en) * | 2003-01-28 | 2005-01-13 | Lee Francis Y. | Novel bone graft composite |
| WO2005009348A2 (en) * | 2003-06-25 | 2005-02-03 | Ariad Pharmaceuticals, Inc. | Substituted purine derivatives |
| JP2005060303A (ja) * | 2003-08-12 | 2005-03-10 | Sutaagen:Kk | 不動性骨粗鬆の治療または予防剤 |
| US7862552B2 (en) | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US447256A (en) * | 1891-02-24 | Apparatus for flashing and exhausting incandescent electric lamps | ||
| US4447256A (en) * | 1977-07-20 | 1984-05-08 | Nissan Chemical Industries, Ltd. | N-(Unsubstituted or substituted pyridyl)aminomethylene-diphosphonic acids, herbicidal compositions containing same, their use for herbicides, and process for preparing same |
| IL77243A (en) * | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
| DK126888A (da) * | 1987-03-10 | 1988-09-11 | Yamanouchi Pharma Co Ltd | Bisphosphonsyrederivater og terapeutiske praeparater indeholdende disse forbindelser |
| KR880011136A (ko) * | 1987-03-11 | 1988-10-26 | 모리오까 시게오 | 아졸- 아미노메틸렌 비스포스폰산 유도체 |
-
1994
- 1994-06-09 SE SE9402001A patent/SE9402001D0/sv unknown
-
1995
- 1995-02-06 UA UA97010075A patent/UA43918C2/uk unknown
- 1995-06-02 BR BR9508185A patent/BR9508185A/pt not_active IP Right Cessation
- 1995-06-02 CN CN95193416A patent/CN1077792C/zh not_active Expired - Lifetime
- 1995-06-02 DK DK95920122T patent/DK0762883T3/da active
- 1995-06-02 ES ES95920122T patent/ES2162919T3/es not_active Expired - Lifetime
- 1995-06-02 PL PL95317612A patent/PL180705B1/pl unknown
- 1995-06-02 WO PCT/FI1995/000315 patent/WO1995033466A1/en active IP Right Grant
- 1995-06-02 JP JP50040096A patent/JP3883137B2/ja not_active Expired - Lifetime
- 1995-06-02 AU AU25698/95A patent/AU691616B2/en not_active Expired
- 1995-06-02 CZ CZ19963561A patent/CZ291477B6/cs not_active IP Right Cessation
- 1995-06-02 KR KR1019960706991A patent/KR100363692B1/ko not_active IP Right Cessation
- 1995-06-02 NZ NZ287094A patent/NZ287094A/en not_active IP Right Cessation
- 1995-06-02 DE DE69523914T patent/DE69523914T2/de not_active Expired - Lifetime
- 1995-06-02 RU RU97100161/14A patent/RU2154482C2/ru active
- 1995-06-02 US US08/750,355 patent/US5866556A/en not_active Expired - Lifetime
- 1995-06-02 EE EE9600191A patent/EE03475B1/xx unknown
- 1995-06-02 EP EP95920122A patent/EP0762883B1/en not_active Expired - Lifetime
- 1995-06-02 PT PT95920122T patent/PT762883E/pt unknown
- 1995-06-02 AT AT95920122T patent/ATE208622T1/de active
- 1995-06-02 SK SK1572-96A patent/SK282650B6/sk not_active IP Right Cessation
- 1995-06-02 HU HU9603375A patent/HU228618B1/hu unknown
- 1995-06-02 RO RO96-02286A patent/RO119433B1/ro unknown
-
1996
- 1996-12-02 IS IS4392A patent/IS1801B/is unknown
- 1996-12-06 NO NO19965228A patent/NO311069B1/no not_active IP Right Cessation
-
1997
- 1997-01-06 BG BG101116A patent/BG63104B1/bg unknown
-
1998
- 1998-12-17 HK HK98113970A patent/HK1012572A1/xx not_active IP Right Cessation
- 1998-12-23 US US09/219,692 patent/US6083938A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL192562C (nl) | Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat. | |
| FI85490B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara inositoltrifosfat. | |
| Martin et al. | Bisphosphonates-mechanisms of action | |
| IL268885A (en) | Prodrugs carbidopa and l dopa and methods for use in the treatment of Parkinson's disease | |
| US5015634A (en) | Method of treating tissue damage with inositol triphosphate | |
| EP0354806A2 (en) | Heterocyclic bisphosphonic acid derivatives | |
| NO311069B1 (no) | Pyridylbisfosfonater for anvendelse som terapeutisk middel | |
| JP6010196B2 (ja) | オキサゾリジノン含有二量体化合物、組成物、ならびに作製および使用方法 | |
| PL174726B1 (pl) | Nowe związki fosfonokarboksylanowe i środek farmaceutyczny do leczenia nieprawidłowego metabolizmu wapnia i fosforanów | |
| JPS63239291A (ja) | 新規ヘテロ環置換ジホスホネート化合物、医薬組成物並びにカルシウム及びリン酸代謝異常の治療方法 | |
| CA2152693A1 (en) | Therapeutic composition for pancreatitis | |
| EP0230068A2 (en) | Use of a geminal diphosphonic acid compound to prepare a medicament | |
| GB2096889A (en) | Pharmaceutical composition containing 6-amino-1-hydroxyhexane-1,1-diphosphonic acid | |
| FI87652B (fi) | Foerfarande foer framstaellning av oktahydropyridindifosfonsyror och farmaceutiskt godtagbara salter och estrar daerav | |
| JP2568999B2 (ja) | ｇｅｍ−ジホスホネ−トを含有する薬学的組成物 | |
| CA2192456C (en) | Pyridylbisphosphonates for use as a therapeutical agent | |
| MXPA96006180A (en) | Piridilbisphosphonates to be used as a therapist agent | |
| GB2111503A (en) | Phosphoramide derivatives, process for producing the same and medicines containing the same | |
| FI117053B (sv) | Pyridylbisfosfonater att användas som terapeutiskt medel | |
| US3703579A (en) | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue | |
| DK173973B1 (da) | Geminale heterocycliske diphosphonsyrer og farmaceutisk acceptable salte heraf samt farmaceutiske sammensætning omfattende samme | |
| CN108815117A (zh) | 一种镇痛药物组合物及其制备方法 | |
| JPH10218767A (ja) | 骨疾患治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |